SHANGHAI (Reuters) – Pfizer and Merck have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China, local media reported on Tuesday citing pricing information published …
paxlovid
-
-
By Manas Mishra and Michael Erman (Reuters) – Clarity from Pfizer Inc this week on whether China’s relaxation of its Zero-COVID policy and the surge in infections there will lead …
-
(Reuters) – Pfizer Inc is working with Chinese authorities to send its COVID-19 pill, Paxlovid, to the country that is dealing with a surge in COVID-19 cases, Chief Executive Officer …
-
By Julie Steenhuysen CHICAGO (Reuters) – The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc’s antiviral drug Paxlovid as the first treatment it will study …
-
By Nancy Lapid (Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has …
-
By Deena Beasley (Reuters) – Use of Pfizer Inc’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health …
-
By Julie Steenhuysen CHICAGO – Additional reports of patients with long COVID who were helped by Pfizer Inc’s oral antiviral treatment Paxlovid offer fresh impetus for conducting clinical trials to …
-
By Julie Steenhuysen CHICAGO – Reports of two patients who found relief from long COVID after taking Pfizer Inc’s antiviral Paxlovid, including a researcher who tested it on herself, provide …